Loading...
Loading...
- GlaxoSmithKline Plc (NYSE: GSK) expects profit to fall this year, as the company cites an increase in research spending in pursuit of the next blockbusters.
- Earnings per share are expected to decline by a mid-to high-single-digit percentage. It is planning to more than double the number of blockbuster drugs in its portfolio by 2026.
- Turnover for 2020 inched up 1% to £34 billion, driven by a 12% in pharmaceuticals and offset by a 3% dip in pharmaceuticals and lower vaccine revenue.
- Profit before tax was 12% higher at £6.9bn, while earnings per share surged 23% to 115.5p due to cost control measures.
- The company plans to announce a new distribution policy, implemented from 2022 onwards, to support growth and investments. Expected to be lower than the current value. Shareholders will receive a final dividend of 80p per share in FY2021.
- GSK added that it is on track to separate two new standalone Biopharma and Consumer Healthcare companies in 2022 to save £300 million annually while it also made £1.1 billion from divestments.
- Earlier today, GSK announced a COVID-19 vaccine collaboration with CureVac NV against variants of the coronavirus.
- Price Action: GSK shares are trading lower by 5.59% at $35.49 on the last check Wednesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in